ESMO: Merck, in flurry of studies, shows Keytruda's power and limitations
Fierce Pharma
OCTOBER 24, 2023
At this year’s congress of the European Society for Medical Oncology (ESMO), Merck & Co. Across four separate studies, Merck’s PD-1 juggernaut Keytruda—in combination with other cancer meds—charted complete and partial wins in cervical cancer, early breast cancer and stomach cancer.
Let's personalize your content